Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Co-dydramol is a fixed-dose combination analgesic containing dihydrocodeine tartrate and paracetamol (acetaminophen). Dihydrocodeine is a semi-synthetic opioid analgesic with potency similar to codeine, acting primarily as an agonist at mu-opioid receptors to modulate pain perception. Paracetamol is a non-opioid analgesic and antipyretic that likely exerts its effects through the inhibition of cyclooxygenase (COX) enzymes within the central nervous system, reducing prostaglandin synthesis. The combination is used for the treatment of moderate pain where simpler analgesics have proven insufficient. It is widely available in the United Kingdom as a generic medication and under various brand names.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on co-dydramol.